Phase 2 N=30 Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
Smoldering Multiple Myeloma
Primary: Rate of Patients Achieving an Objective Response — 0; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=100 Study Comparing Two Types of Ports in Patients With Cancer Receiving Intravenous Chemotherapy
Unspecified Adult Solid Tumor, Protocol Specific · Vascular Access Device Complications
Primary: Port Failure Within 12 Months of Port Insertion — 16.1; 13.8 percentage of patients
Phase 2 N=10 Calcineurin Inhibitor (CNI)-Free Immunosuppressive Regimen in T1D Patients Receiving Islet Transplantation
Type 1 Diabetes
Primary: The Proportion of Insulin Free Patients 3 Years After the Last Islet Infusion — 4 participants
Phase 2 N=6 Sirolimus for Advanced Age-Related Macular Degeneration
Age-Related Macular Degeneration · Geographic Atrophy
Primary: Rate of Change in Area of Geographic Atrophy (GA), Based on Masked, Digital Grading of Fundus Photography by an External Reading Center, in the Study Eye at 12 Months…
Phase 2 N=95 A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy
Excessive Daytime Sleepiness · Narcolepsy
Primary: Change From Baseline in Maintenance of Wakefulness Test (MWT) Score at Day 21 of Stable Dosing Phase — 6.30; 5.81; 1.29; 1.10 minutes — p=0.418
Phase 2 N=21 Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal Infection
Aspergillosis, Aspergilloma
Primary: Area Under the Plasma Concentration-time Profile From Time Zero to Twelve Hours at Steady-State (AUC12,ss) Following IV Administration — 51.92; 83.39; 17.27 μg*h/mL
Phase 2 N=41 Human Brain Natriuretic Peptide (BNP) (or Nesiritide) to Help Heart, Kidney and Humoral Function.
Left Ventricular Diastolic Dysfunction
Primary: Change in Urinary Sodium Excretion in Response to Saline Load — 381.6; -10.5 mEq/minute — p=<0.001
Phase 2 N=10 Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
Leukemia, Acute Myelogenous (AML) · Leukemia, Acute Lymphocytic (ALL) · Leukemia, Chronic Myelogenous (CML)
Primary: Toxicity — 5 participants
Phase 2 N=55 AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin
Solid Tumors · Advanced Cancer
Primary: Number of Participants With Adverse Events in Sequential Cohort Dose Escalation Study of AMG 531 Following Chemotherapy — 0; 0; 1; 4 participants
Phase 2 N=49 Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device
Rheumatoid Arthritis (RA)
Primary: Dose-Normalized AUC[0-Inf] for MTX — 109.47; 140.84; 136.45 ng*hr/mL/mg
Phase 2 N=98 Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentages of Patients With Treatment-emergent or Serious Adverse Events — 54.2; 63.6; 65.2; 60.9 percentage of participants
Phase 2 N=75 Meclizine as a Potential Smoking Cessation Treatment
Smoking Cessation
Primary: Percentage of Change in Expired Air Carbon Monoxide (CO) at End of Week 1 — 1.73; -14.11; -.63 percentage change
Phase 2 N=46 Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
Lymphoma
Primary: 12-Month Progression-Free Survival (PFS) — 0.44 probability
Phase 2 N=194 ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients
Exudative Age-Related Macular Degeneration
Primary: Change From Baseline at Month 1 in Central Subfield Thickness (CSFT) as Measured by Spectral Domain Ocular Coherence Tomography (SD-OCT) — -142.3; -181.6; -175.6; -174.9…
Phase 2 N=21 Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
Multiple Myeloma · Non-Hodgkins Lymphoma · Hodgkins Disease
Primary: Number of Participants Who Achieved > or Equal to 2 X 10(6)CD34+ Cells/kg Within 3 Days of Apheresis After Receiving Plerixafor With G-CSF. — 15 participants